Literature DB >> 7948556

Streptomycin and alternative agents for the treatment of tularemia: review of the literature.

G Enderlin1, L Morales, R F Jacobs, J T Cross.   

Abstract

Because of the recent lack of availability of streptomycin--currently considered the drug of choice for the treatment of tularemia--we reviewed the literature on alternative drugs that have been used for this purpose. In addition, we reviewed data on the in vitro susceptibility of Francisella tularensis to a wide variety of agents. The rate of cure for streptomycin was 97%, with no relapses. For gentamicin and tetracycline, respectively, the rates of cure were 86% and 88%, the rates of relapse were 6% and 12%, and the rates of failure were 8% and 0. The duration of therapy with gentamicin and a delay in its initiation may have affected outcome in severe cases. For chloramphenicol and tobramycin, cure rates were 77% and 50%, respectively; relapse rates were 21% and 0; and failure rates were 2% and 33%, respectively. Treatment with imipenem/cilastatin was successful in one case, and that with ciprofloxacin or norfloxacin was successful in six cases; in contrast, therapy with ceftriaxone was ineffective in eight cases. On the basis of this review, we conclude that gentamicin is an acceptable alternative to streptomycin for the treatment of tularemia.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7948556     DOI: 10.1093/clinids/19.1.42

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  48 in total

Review 1.  Use of aminoglycosides in treatment of infections due to intracellular bacteria.

Authors:  M Maurin; D Raoult
Journal:  Antimicrob Agents Chemother       Date:  2001-11       Impact factor: 5.191

2.  Review of Restricted Experiment Requests, Division of Select Agents and Toxins, Centers for Disease Control and Prevention, 2006-2013.

Authors:  Jacinta Smith; Denise Gangadharan; Robbin Weyant
Journal:  Health Secur       Date:  2015-09-08

3.  Intranasal interleukin-12 treatment promotes antimicrobial clearance and survival in pulmonary Francisella tularensis subsp. novicida infection.

Authors:  Michael A Pammit; Varija N Budhavarapu; Erin K Raulie; Karl E Klose; Judy M Teale; Bernard P Arulanandam
Journal:  Antimicrob Agents Chemother       Date:  2004-12       Impact factor: 5.191

4.  Tularemia and once-daily gentamicin.

Authors:  Ali Hassoun; Richard Spera; John Dunkel
Journal:  Antimicrob Agents Chemother       Date:  2006-02       Impact factor: 5.191

5.  Tularemia presenting as pulmonary nodules in an immunocompromised patient.

Authors:  Tony Alias; Mohammad Kazem Fallahzadeh; Mezgebe Berhe
Journal:  Proc (Bayl Univ Med Cent)       Date:  2017-04

6.  Oropharyngeal tularemia.

Authors:  Julia Steinrücken; Peter Graber
Journal:  CMAJ       Date:  2013-07-15       Impact factor: 8.262

7.  AR-13, a Celecoxib Derivative, Directly Kills Francisella In Vitro and Aids Clearance and Mouse Survival In Vivo.

Authors:  Ky V Hoang; Haley E Adcox; James R Fitch; David M Gordon; Heather M Curry; Larry S Schlesinger; Peter White; John S Gunn
Journal:  Front Microbiol       Date:  2017-09-11       Impact factor: 5.640

8.  A case of tularemia after an endurance run in a non-endemic region.

Authors:  R Meckenstock; A Therby; A Le Monnier; D Khau; S Monnier; B Pangon; A Greder-Belan
Journal:  Infection       Date:  2012-10-17       Impact factor: 3.553

9.  [Fever and lymphadenopathy. Report of 4 cases of tularemia].

Authors:  C Bloch; A Friedl; F Zucol; A Widmer; N Khanna
Journal:  Internist (Berl)       Date:  2013-04       Impact factor: 0.743

Review 10.  Versatility of aminoglycosides and prospects for their future.

Authors:  Sergei B Vakulenko; Shahriar Mobashery
Journal:  Clin Microbiol Rev       Date:  2003-07       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.